List view / Grid view



28 August 2011 Prof Antonio Dans

Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke

28 August 2011 | By

New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…